A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD
To preliminarily evaluate whether there is a survival benefit of surufatinib combined with camrelizumab and mFOLFOX6 as the second-line treatment for advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer
Advanced Pancreatic Cancer
DRUG: Surufatinib 250mg/d qd once daily
objective response rate (ORR), Defined as percentage of participants achieving assessed complete response (CR) and partial response (PR) by the investigator according to the RECIST 1.1., Time Frame: up to 24 months
disease control rate (DCR), DCR was defined as the percentage of participants who have a confirmed complete response（CR） or partial response（PR） or stable disease（SD） per RECIST 1.1 as assessed by investigator, Time Frame: up to 24 months|Progression-Free Survival (PFS), PFS is defined as the time from enrollment to the first documented disease progression or death due to any cause, whichever occurs first. Responses are according to the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) as assessed by investigator, Time Frame: up to 24 months|overall survival (OS), OS is the time from enrollment to death due to any cause., Time Frame: up to 24 months|quality of life (QoL), Assessing the quality of life of cancer patients by QLQ-C30, Time Frame: up to 24 months|adverse events (AE), overall incidence of adverse events (AE); incidence of grade 3 or higher AE; incidence of severe adverse events (SAE); incidence of AEs leading to discontinuation of drug use; incidence of AEs leading to suspension of drug use., Time Frame: up to 24 months
Second-line clinical study of surufatinib in combination with Caralizumab advanced pancreatic cancer